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ment (SEM) and 1/2 standard deviation (1/2SD)) and anchor
methods against the smallest change on the global rating of
change. Missing data were imputed using last observation carried
forward. RESULTS: Internal consistency (a = 0.940) and con-
struct validity (SF-36 Role Function r = -0.66; Vitality r = 0.62,
Social Function r = 0.71, Pain r = 0.64, SNOT-16 r = 0.67 all
P < 0.001) were conﬁrmed with strong correlations. The AIA
was sensitive (ES = 0.90; SRM = 0.82). The MID estimated by
the anchor method was 2.63; but MID was lower by distribu-
tional estimates (SEM = 1.39, 1/2SD = 2.84). CONCLUSIONS:
The study conﬁrms the good psychometric properties of the AIA
in patients with acute bacterial sinusitis and demonstrates the
sensitivity and MID for this measure. Distributional MID esti-
mates conﬁrmed the anchor based approach.
PIN49
INTERNATIONAL DEVELOPEMENT OF A NEW
HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRE
SPECIFICTO HIV/AIDS—PROQOL HIV STUDY
Duracinsky M1,Acquadro C2, Berzins B3, Hermann S4, Le Coeur S5,
Fournier I6, Diouf A7, Kohli R8, Chassany O9
1Centre Hospitalier Universitaire de Bicetre, Le Kremlin-Bicetre,
France, 2AP HP, Paris, France, 3Northwestern University, Chicago,
Chicago, IL, USA, 4Royal Perth Hospital, Perth, Australia, 5Institut
National d’Etudes Démographiques (INED), Chiang Mai,Thailand,
6Institut Pasteur, Phnom Penh, Cambodia, 7Centre de Recherche
Clinique de Fann (CRCFP), Dakar, Senegal, 8National AIDS Research
Institute, Pune, India, 9Assistance Publique—Hopitaux de Paris, Paris,
France
OBJECTIVES: Most Heath-Related Quality of Life (HRQL)
questionnaires speciﬁc to HIV/AIDS were developed when HIV
was a deadly disease. They do not adequately measure the
impact of the disease and its treatment on People Living With
HIV/AIDS (PLWA) anymore. Relevant domains are missing
such as perception about treatment, impact of side effects, lipo-
dystrophy and sleep. Psycho-social impact, especially stigma, is
under-evaluated. The objective is to develop a new Patient-
Reported Outcomes (PRO) questionnaire to measure the
HRQL of PLWA in different countries using an item bank
developed with patients. METHODS: The conceptual frame-
work was identiﬁed on the basis of patients’ interviews. To
capture the cultural differences in patients’ perceptions, the
interviews were held in the ﬁve continents: Africa (Senegal),
America (Brazil, USA), Australia, Asia (Thailand, China, Cam-
bodia, India) and Europe (France). All interviews were
recorded, transcribed and translated into English or French.
Important verbatim were selected, transformed into items and
organized into a questionnaire developed in French and in
English. ). All interviews were recorded, transcribed and trans-
lated into English or French. Important verbatim were selected,
transformed into items and organized into a questionnaire
developed in French and in English. RESULTS: A total of 148
patients were interviewed (47% women), and PRO concepts
important to the patients were identiﬁed. An endpoint model
was designed to explain the relations between PROs: health
status, symptoms, side effects and HRQL domains. Cultural
differences were identiﬁed in daily activities, stigma and rela-
tions with family and friends. 300 items were generated in
French and in English and organized into a 24-domain item
bank. Item reduction to a 70-item questionnaire was done with
experts. Full linguistic validation process was performed. CON-
CLUSIONS: A new PRO questionnaire speciﬁc to HIV was
developed. The international development from an early step
will enable a better cultural relevance and has improved the
translatability of the source questionnaires (French and English)
into the target languages. The international psychometric vali-
dation study with 900 patients is ongoing.
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OBJECTIVES: To develop an understanding of the adoption
decision process for vaccines, and the role of value demonstration
(cost-effectiveness) in that process. METHODS: The literature
was searched for a) general information on decision criteria
applicable to vaccines; b) information speciﬁc to vaccine value
demonstration; and c) cost-effectiveness analyses for HPV, pneu-
mococcal disease, and dTpa as examples of vaccines recently
adopted. Informationwas extracted by two reviewers to outline a)
the general factors affecting vaccine adoption, and b) the role of
value demonstration, and (c) what inﬂuences vaccine value dem-
onstration. RESULTS: Four published guidelines were identiﬁed
which outline factors to consider in the vaccine adoption process.
Thesewere combined to produce the following framework: 1) The
disease: is it a high priority, and an important public health
issue? 2) The vaccine: is it safe and effective in reducing disease
incidence? 3) The value: is it cost-effective? 4) The socio-political
climate: what are the concerns of the major stakeholders and how
can they be addressed? and 5) The feasibility: are there sufﬁcient
resources to adopt the vaccine? Factors identiﬁed as important in
determining vaccine cost-effectivenesswere: Vaccine efﬁcacy—the
more effective, including herd immunity effects, the higher the
perceived value; Disease incidence—the higher the incidence,
the greater the potential beneﬁt and therefore value; Disease
sequalae—the more severe and frequent the sequalae, the higher
the potential value in avoiding the condition; and Duration of
immunity—the longer the duration, the higher the value as fewer
boosters are required. CONCLUSIONS: While we were able to
synthesise a framework to describe the vaccine adoption process,
no information was found in the literature on how the elements of
that framework might be combined, ranked or weighted to reach
a decision. Further research into the relative weighting of these
factors is warranted.
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OBJECTIVES:Assess the severe sepsis diagnosis andmanagement
practices based on the SSC guidelines and quality indicators.
Determine the case severity level and outcomes of severe sepsis in
an inner city hospital setting. Ascertain the average direct cost of
severe sepsis hospitalization in this setting. METHODS: Using an
explanatory cross-sectional evaluation design, demographic,
administrative, clinical and laboratory data of all patients with
physician- diagnosed sepsis admitted during March–May 2007
were reviewed. The SSC-IHI severe sepsis screening/chart mea-
surement tools and quality indicatorswere used for data collection
and performance assessment respectively. Process measures were;
time-to-blood culture, blood culture-antibiotic sequence, time-to-
antibiotic, CVP goal, CV Oxygen saturation goal, Low-dose
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